0000000000807359

AUTHOR

A. Saggioro

showing 2 related works from this author

A new 1-week therapy for Helicobacter pylori eradication: rani- tidine bismuth citrate plus two antibiotics

1997

Background: One-week triple regimens are currently the most recommended therapy for the eradication of Helicobacter pylori. No previous study has evaluated the efficacy of a short-term regimen combining ranitidine bismuth citrate with two antibiotics. Methods: Seventy-two consecutive H. pylori-positive dyspeptic patients were recruited for this randomized, three-centre, open, parallel-group study. They were subdivided into two groups receiving either ranitidine bismuth citrate 400 mg b.d. + clarithromycin 250 mg b.d. and metronidazole 500 mg b.d. (group A) or ranitidine bismuth citrate 400 mg b.d. + clarithromycin 250 mg b.d. and metronidazole 250 mg q.d.s (group B) for 1 week. H. pylori in…

Malemedicine.medical_specialtyRanitidineGastroenterologyGroup BHelicobacter InfectionsRanitidineClarithromycinMetronidazoleClarithromycinInternal medicinePyloric AntrummedicineHumansPharmacology (medical)Antibacterial agentHelicobacter pyloriHepatologybiologybusiness.industryGastroenterologyHelicobacter pyloribiology.organism_classificationAnti-Bacterial AgentsSurgeryMetronidazoleRegimenHistamine H2 AntagonistsRanitidine HydrochlorideDrug Therapy CombinationFemalebusinessBismuthmedicine.drugAlimentary Pharmacology and Therapeutics
researchProduct

Oral cromolyn sodium in comparison with elimination diet in the irritable bowel syndrome, diarrheic type. Multicenter study of 428 patients.

1995

In a significant number of patients affected by the irritable bowel syndrome, an adverse reaction to food is proposed to be a causative factor. A diet that eliminates the offending foods is the obvious treatment for such adverse reactions. Compliance with a dietetic regimen is often poor and sometimes not completely free from risks.Since the diarrheic type of irritable bowel syndrome seems mainly affected by food intolerance, and previous observations suggested that oral cromolyn sodium is effective in such patients, a multicenter therapeutic trial in the diarrheic type of irritable bowel syndrome was carried out in 346 of 409 patients with this disease, to evaluate the effects of oral crom…

AdultDiarrheaMalemedicine.medical_specialtyAdolescentmedicine.medical_treatmentAdministration OralColonic Diseases FunctionalGastroenterologyOral administrationInternal medicineElimination dietAnti-Allergic AgentsCromolyn SodiummedicineHumansAdverse effectIrritable bowel syndromeAgedAged 80 and overChemotherapybusiness.industrydigestive oral and skin physiologyGastroenterologyCromolyn SodiumMiddle Agedmedicine.diseasePrognosisDiarrheaTreatment OutcomeMulticenter studyFemalemedicine.symptombusinessFood HypersensitivityScandinavian journal of gastroenterology
researchProduct